Abstract Library

#2955 Development of an EORTC Quality of Life Questionnaire for Patients with Pancreatic Neuroendocrine Tumours: Phases 1-3

Introduction: Measuring quality of life (QoL) in Pancreatic Neuroendocrine Tumours (pNET) involves assessing issues from symptoms, disease and treatment. The validated gastrointestinal NETs module (EORTC QLQ-GINET21) is used with EORTC QLQ-C30 but there are concerns it inadequately measures QoL in pNET.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Friend E, Gray D, Fernández Ortega P, McNamara M, Kaltsas G,

Keywords: research, neuroendocrine, insulinoma, gastrinoma, non-functioning, VIPoma, Glucagonoma, questionnaire, quality of life,

#2695 Different Treatment Options for Patients with Advanced Gastrointestinal Neuroendocrine Tumors

Introduction: Low sensitivity to chemotherapy leaves open question of optimal approach to drug therapy of neuroendocrine tumors (NETs). Somatostatin analogues (SSA) (octreotide, lanreotide) and mTOR inhibitors are successfully used in treatment.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Isiangulova A, Khasanov R,

Keywords: neuroendocrine tumors, somatostatin analogues, target therapy, everolimus, systemic therapy,

#2279 Expression of FOXM1 in G3 Neuroendocrine Tumors (NET G3) and G3 Neuroendocrine Carcinomas (NEC G3) of the Pancreas and the Intestine

Introduction: G3 gastroenteropancreatic neuroendocrine tumors (G3 NET) and carcinomas (G3 NEC) differ considerably concerning their biological behavior and patients outcome. Whereas the WHO2017 classification for pancreatic NETs proposes a distinction of both groups using the Ki-67 proliferation marker (Klöppel et al. Reviews and Reports 2017), a useful marker for the subclassification of G3 intestinal NETs have not been recommended until now.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Briest F

Authors: Briest F, Konukiewitz B, Anlauf M, Klöppel G, Grabowski P,

Keywords: gastroenteropancreatic neuroendocrine tumors, GEP-NET, NET G3, NEC G3, Tumor marker, FOXM1, Ki-67, differentiation,

#2015 Single-Institutional Review of Non-Pancreatic GI Neuroendocrine Tumors

Introduction: Neuroendocrine tumors (NETs) most commonly occur in the digestive tract with an incidence of 3.56 per 100,000 with 94% of those being non pancreatic.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: el chami a

Authors: El Chami A, El Halabi I, Charaffedine M, Temraz S, Mukherji D,

Keywords: neuroendocrine tumor, gastrointestinal, location, prognosis,

#1495 Everolimus for Advanced, Progressive, Nonfunctional Neuroendocrine Tumors (NET) of the Gastrointestinal (GI) Tract: Efficacy and Safety from a RADIANT-4 Subgroup Analysis

Introduction: Everolimus (EVE) demonstrated progression-free survival (PFS) benefit of 7.1 months compared to placebo in the phase 3 RADIANT-4 study in patients (pts) with advanced, well-differentiated, progressive, nonfunctional NET.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Singh S

Authors: Singh S, Carnaghi C, Buzzoni R, Raderer M, Lahner H,

Keywords: Everolimus, progression-free survival, gastrointestinal NET,